SEVENTH MEETING OF THE UNAIDS MONITORING AND EVALUATION REFERENCE GROUP (MERG)
Geneva 28-29 July 2003 Switzerland
DRAFT SUMMARY REPORT TABLE OF CONTENTS
1. Introduction……………………………………………. …………….3
2. Objectives of the meeting…………………………………….. ……...3
3. Main points/comments made and conclusions reached during discussions on presentations...... ……………….. ………..4
3.1. Indicator guidelines discussion points………….…... …………………………………..4 3.2. Working groups…………………………………….…………………………………... ….5 3.3. UNGASS Country reports…………………………. ……………………………………...6 3.4. Survey on coverage rates for essential services: Preliminary results of the AIDS Program Index (API) second round…. ……………6 3.5. Global AIDS M&E Support Team (GAMET)……. …………………………………….6 3.6. Global Fund to fight AIDS, TB, and Malaria (GFATM)………………. ……………..7 3.7. Country Response Information System (CRIS) ………………………………………....7 3.8. Estimates and modelling…………………………………………………………………..8 3.9. UN System Strategic Plan (UNSSP) ……………………………………………………...8
4. New M&E challenges
4.1. MERG specific……………………………………………………………....……….…. …8 4.2. General…………………………………………………………………....………. ……...... 9 4.3. Immediate Actionable Items……………………………………………………. ………...9
2 ANNEXES
Annex 1. Working Groups on indicators, summaries submitted by rapporteurs A. Young People B. PMTCT C. Care and Support
Annex 2. Provisional Agenda
Annex 3. List of Participants Annex 4. Unable to Attend
3 1. Introduction
The purpose of this report is to provide a summary of the issues addressed during the seventh meeting of the UNAIDS Monitoring and Evaluation Reference Group (MERG), held in Geneva during 28 – 29 July, 2003. The outline of the report follows to the extent possible the meeting agenda (see Annex 2).
A diverse set of monitoring and evaluation (M&E) experts were invited to participate in the meeting, representing academic/research institutes, bilateral agencies, the Global Fund to Fight AIDS, TB and Malaria Secretariat (GFATM), national governments, NGOs, US funded projects, UNAIDS Cosponsors, other UN agencies, and UNAIDS Secretariat (see Annex 3).
After a brief self-introduction by each participant, Kathleen Cravero (Deputy Director, UNAIDS) welcomed the participants. Ms. Cravero emphasized the unique position of the MERG as an informal group of the Programme Coordination Board (PCB)—that provides guidance and direction on the harmonization of monitoring and evaluation approaches. She also emphasised that M&E is one of the five key UNAIDS functions and that the status of the MERG needs to be further clarified.
The seventh MERG was chaired by Dr. Paul DeLay (Director, Monitoring & Evaluation UNAIDS Secretariat). In his remarks, Paul DeLay spoke about how the MERG has evolved as an M&E resource group. Initially, the role of the MERG was to advise the Secretariat and the PCB on the monitoring and evaluation of UNAIDS’ activities, but over time, the MERG has expanded its mandate to include the review and endorsement of new indicators, the standardization of indicators and surveillance methodologies, and to advise the global community on monitoring and evaluation systems at global and country level. The MERG is now viewed as one of the pre- eminent resource groups on monitoring and evaluating the response to the HIV/AIDS pandemic.
The provisional agenda was next reviewed and agreed upon.
The sections that follow will cover the (2) objectives of the seventh MERG; present the (3) main points/comments made and conclusions reached during the discussions on the presentations; and (4) summarize the identified M&E challenges – MERG specific, and general to the field of M&E of HIV/AIDS program/projects along with the immediate actionable items.
This MERG meeting report and the presentations delivered will be available in October 2003 at the UNAIDS M&E webpage: http://www.unaids.org/en/in+focus/monitoringevaluation/m_e+resource+groups.asp
2. Objectives of the meeting
4 The objectives of the seventh MERG were to: i) review and approve new indicator guidelines; ii) review current global reporting efforts and activities to support to country monitoring and evaluation programs; iii) review/revise the scope of work and composition of the MERG as an M&E resource group.
3. Main points/comments made and conclusions reached during discussions on presentations
3.1. Indicator guidelines discussion points
The focus of this section was on indicators national AIDS prevention and control programs for the following groups/areas: young people; orphans and vulnerable children (OVC); care and support; injecting drug use (IDU); and, PMTCT.
Young people: The reliability of reporting through school-based surveys tends to be inadequate and/or weak. The relevance of indicators depends on how well a program is defined. Age-group should determine the selection of the indicator set. Gender stratification should be taken into account. The UNGASS Core Indicators should be widely promoted. Clear reference to other guidelines should be made as a way to avoid overlap. Reporting on the 10 to 14 year old age cohorts may have questionable validity. More work needs to be done with these younger age groups to determine the optimum methods for ascertaining risk behaviours.
OVC: There are different definitions of “vulnerability” in the OVC and the Care and Support guidelines. A common understanding of vulnerability is necessary. Currently, the most useful indicator for orphans is school attendance. There is consideration of changing the definition of OVC to extend the age range to 18 year old.
Care and Support: Gender issues should be taken into account when determining level of access to treatment. There is a need for greater synchronisation of methods - frequency of surveys and responsibilities, for example, home-based-care and orphan data collection could be carried out by the same researchers. There is a need to address the lack of focus on the private sector. The human capacity indicator should be reconsidered.
5 Concerns were expressed about measuring quality of services and not assessing traditional health care seeking behaviour.
IDU: With regards to HIV/AIDS, it is more important to study IDU than other drug use. With regards to UNGASS Core Indicators, there is a need to make the indicator on coverage the core one and the indicator on IDU behaviour the additional one. The Guide should be modified accordingly
PMTCT: A collaborative process was applied to produce the guide, involving many actors – UN agencies, NGOs etc. The guideline has reached its final stage and needs endorsement. There are six core indicators: two are UNGASS indicators, and four are additional indicators. Reference to “blood safety” issue should be made in the guideline. There was a discussion on the need for an indicator relating to capacity to implement (percent of health care workers trained in PMTCT, and country relevance) Measuring the “cascade” of service utilization was considered critical, i.e. # pregnant women--# pregnant women attending ANC--# of pregnant women counselled--# pregnant women who agree to HIV testing--# pregnant women who return for test results--# pregnant women who receive ARV’s--# infants who receive ARVs.
General observation: Substantial time was devoted to develop the guidelines. The guidelines should be disseminated as soon as possible in order to tap into the momentum. A framework or umbrella introduction should be developed to clarify for national programmes how the various guides should be used and should complement each other. Attempts should be made to avoid overlap with other guidelines, and to make the guidelines as user-friendly as possible for professionals at country-level. It is essential that parallel M&E systems are not established. Every opportunity for consolidating indicators into single measurement tools should be explored.
3.2. Working groups
The main task for the working groups was to discuss the roll out strategy for the guidelines. Summaries submitted by the rapporteurs are available in Annex 1.
Young people:
6 The guide is a useful advocacy tool. Most indicators have been widely field-tested; hence, further field-testing is not necessary. The number of indicators should be reduced. Clarification is needed with regards to cross-references to other guidelines. There is a need to better disaggregate young people in prevention messages - the 10-14 age-group should be removed from the core text as this target group requires special attention. The guide will be revisited by a full-time consultant to finalise the draft (Measure).
PMTCT: The title should remain as is “Guide for preventing the transmission to infants and young children” Indicator on “percent of health care workers trained in PMTCT” should not be applied to all countries. Indicator number four is to be finalised. The guide should mention that blood safety indicators can be found in the UNAIDS National AIDS Program M&E guide. WHO is responsible for finalizing the guide.
Care and Support: Reconsider human capacity indicators - consider naming “care and treatment” instead of “care and support”. There is a need to further field-test the indicators. There is a lack of focus on the private sector. More detail is needed in the tables and templates.
General comments: With regards to AIDS surveys (as part of DHS for example) the idea is to reduce and streamline data collection efforts. Inquiry should be made about lessons learnt from the use of the UNAIDS National AIDS Program M&E guide when further developing the guidelines. There is a need to explore how to best maximise the use and utility of the guidelines.
3.3. UNGASS Country reports
There is a need to explore how to best encourage various sectors to work together on M&E activities in countries that do not have National AIDS Councils. It needs to be determined how to best strengthen UN capacity at country level to facilitate UNGASS reporting. There is a need to develop a strategy that would help sustain the UNGASS process.
7 The guide on the construction of UNGASS DoC indicators should be further adapted to take into account lessons learned with each indicator. A plan for future revisions should be presented at the next MERG meeting
3.4. Survey on coverage rates for essential services: Preliminary results of the AIDS Program Index (API) second round
A meeting will be held with national professionals from 41 priority countries to build consensus around the collected API data. All stakeholders will review data collected through the API and verify/provide estimates for service coverage. An IDU reference group and database may assist in the estimation of population sizes.
3.5. Global AIDS M&E Support Team (GAMET)
GAMET has created an advisory board composed of cosponsors and bilateral agencies. The main role of GAMET is to assist “in-country” M&E coordination and provide technical assistance through a network of consultants (Mobile Support Team) with National AIDS Councils as principal partners. The use of the Mobile Support Teams is seen as an interim solution, and GAMET will explore for the longer term ways to strengthen institutional capacity Currently, 22 countries are covered (mainly MAP countries; only two are non- MAP countries). GAMET facilitates and co-funds also other M&E activities. GAMET’s emphasis is on brokering rather than direct provision of technical assistance, with the long term goal of National AIDS Councils coordinating access to technical resources
3.6. Global Fund to fight AIDS, TB, and Malaria (GFATM)
Additional funds through the GFATM are available to strengthen existing M&E systems. GFATM works with networks of partners to reach objectives. For example, GFATM does not lead any indicator development exercise, but counts on its partners to provide standardised indicator sets. Disbursements based on results: For the first 24 months, focus will be on obtaining results on process indicators; later, the focus will be on coverage and impact indicators. Reporting will probably take place twice-a-year. The CCM advises the GFATM on disbursement of funds while the GFATM makes the final decision. GFATM would like to play a leading role in reaching consensus on one M&E system (one set of national indicators and one reporting system agreed upon by all actors).
8 GFATM strongly endorses M&E – it recommends that five to seven percent of a programme/project budget be assigned to M&E. GFATM supports the idea to expand capacities of “untraditional entities” at country level such as faith-based organizations and the direct transfer of funds to these entities.
3.7. Country Response Information System (CRIS)
Achievements since 6th MERG Meeting: CRIS Version 1.4b (IND) has been released globally. Over 60 countries in four regions have been trained. Programming of Project / resource tracking & Research Inventory databases progressing. Many countries have established M&E working groups. Installation and use of CRIS has commenced in many countries. Global CRIS network has been established, including CRIS focal points within cosponsors.
Challenges that remain: Improved understanding of CRIS and its relationship with other information systems at the global, regional and national levels. National capacity for data collection and analysis leading to improved management of national responses. Data collection of indicators – priority. Resources – hardware and human capacity.
3.8. Estimates/Modelling
It is difficult to compare current estimates with previous due to application of different methodologies – it is only possible to give indication of direction of trends, up or down. Training in these tools has been provided to 132 countries Collaborating partners include the US Centers for Disease Control and Prevention, Family Health International, UNICEF, WHO headquarters, and WHO Regional Offices. This training should result in better estimates and is helping to build capacity in countries.
3.9. UN System Strategic Plan (UNSSP)
The mid-term performance report will be submitted to the UNAIDS PCB in June 2004. The MERG will be kept informed on progress in mid-term performance of United Nations System Strategic Plan 2001-2005.
9 4. New M&E challenges
4.1. Issues specific to the current and evolving role of the MERG
There is a need to further clarify the role of the MERG with regards to harmonization of instruments, consensus on new indicators, prioritization of research agenda, and most importantly how can the MERG contribute to capacity building/TA coordination at the country program level.. There is a need to establish sub-Committees in order to focus the work of the MERG, especially in areas such as: technical issues; training, and capacity development. Composition of the MERG: adequate geographic and thematic representation should be ensured. Authority of the body: it needs to be determined if the MERG is an information sharing forum or a framework where actionable items are identified and addressed. The relationship between the MERG and GAMET needs to be further clarified. It was proposed that GAMET should be considered on of the “implementation arms” of the MERG.
4.2. General
Within the context of scaling-up: there is a need to respond to an increasing demand for strategic information to be used in planning, programming and research. Different types of information needs adds to the complexity of the issue: information that permits assessment of programme performance (monitoring data); information that permits assessment of whether programmes are making a difference (programme evaluation data); and, information on best models for implementation (operations research). Information to assist in the refinement of program activities can be very different from information that is used for accountability to stakeholders. At this stage, emphasis has on developing data collection methods (indicators, survey instruments etc.,) and less on implementation. With regards to the status of health information systems, there is a critical need to build monitoring systems and conduct a global coverage survey of key informants (2003) and a district access/coverage survey with a focus on health systems (2004). There is a need to rethink some measurement issues, mainly second generation surveillance and self-reported risk behaviour in household surveys. A greater focus on evaluation is needed in order to be able to scale-up, measure impact, and plan well. Surveillance should be conceptually integrated with M&E activities.
10 Coordination at both global and country levels should be improved. Stronger evaluation efforts should be made in the area of impact of Behavioural Change programs. Decentralisation of M&E activities need to take into consideration the differing data needs at local and national levels, and sensitisation and skills building is needed at local level. Guidelines are also needed for district level use.
4.3. Immediate Actionable Items
UNAIDS will review the TOR for the MERG and incorporate the comments that were provided during this meeting Subgroups will be established based on perceived needs. Two examples of possible subgroups are: Training Harmonization and Coordination Group” and the “Rapid Intervention Technical Group.” The three indicator guideline documents are endorsed for dissemination, with the suggested revisions as noted above. The MERG will work with key members to develop a concise “umbrella” document that briefly summarizes the different multiple indicator guidelines, discusses key principles for indicator selection, and provides illustrative models where indicators from these different thematic areas can be consolidated into single surveillance activities. This will be disseminated along with the new indicator guidelines before the end of the calendar year The next MERG meeting will be convened within the next 6 to 12 months.
11 12 13 14 15 ANNEX 1
Working Groups on indicators, summaries submitted by rapporteurs.
A. Summary of sub-group meeting on Young People indicators Submitted by Rapporteur: Cyril Pervilhac, WHO
1. The working group on Young People confirmed the need for such a guide as an important advocacy tool to complement other Guides and recommends for this reason to carefully cross- reference other materials (e.g. indicators) used.
2. The 21 “core” indicators identified, among a total 37 indicators, have largely the ones which are currently being used and have been validated and do not need any field testing. The list of indicators needs to be reduced among all types of indicators (e.g. MTCT has 6 core, and OVC has 10). There are too many “Health Service Indicators” and the most important ones need to be identified and combined.
3. The working group suggests not to include the 10-14 years old indicators. This delicate decision was queried and discussed, and agreed upon in plenary. The group acknowledged that the 10-14 years old group is recognised to be an important intervention group. This age group is currently covered by the MGD/ UNGASS indicators on life skills/ trained teachers and were therefore included in the draft Guide, and the Guide will include those related to life skills.
The group recognises the importance of issues like connectedness and regulations, yet, it is not clear how the information collected informs future programmes for action, nor is it clear if tools work in developing country settings (in contrast to the recent experience gathered in a few industrialised countries). These types of indicators, in consequence, need further research and field testing and cannot at this stage be broadly recommended to NAPs, in comparison to the other indicators. In addition, MACRO recommend the use of special surveys (quantitative and qualitative mix with parent’s or schools consent) to work with this age group as per the present experience in four countries in Sub-Saharan Africa with the Allan Guttmacher Institute. A special section in the Guide can recommend and refer to recommended indicators (e.g. p. 2 nb 5 to 8 of Table on Indicators).
4. The essential tool used for Young People is Household surveys among 15-24, and this needs to be made clear in the Guide. In some cases school surveys and surveys of children in institutions (small proportion) can be used. School sampling should not be part of the Guide but can be referred to.
5. Indicators on IDU in young people will be further refined with indicators 12, 13, 14 to be replaced by UNGASS IDU indicators (Karl Dehne’s inputs).
6. Rolling out: Measure/ Evaluation will identify and support a full-time consultant to revisit the draft in September to mid-October as per recommendations of the group. A desk review will be reviewed in the following month and a final document produced
16 in December. The group recommends an “umbrella” document to serve as an introduction to all the Guides to facilitate the understanding how they complement each other.
B.
Summary of sub-group meeting on PMTCT indicators Submitted by Rapporteur: Mary Mahy, UNICEF
The five general points made from the group included the following:
1. The title would stay as “guide for preventing the transmission to infants and young children”. Even though this would seem to include blood based transmission this will be kept as is because research is still determining the proportion of infections through blood based transmission. Until the research has been concluded this is a major factor, no indicators on this will be included. In the meantime a note to this affect and stating that indicators for monitoring blood safety indicators could be found in the UNAIDS guide.
2. It was additionally emphasized that the title should not be preventing mother to child transmission because this did not adequately represent the broader reach of the intervention to achieve all four prongs instead of only prong 3.
3. There is still some discussion going on regarding whether core indicator 4 captures coverage adequately. It was pointed out that both indicators 3 and 5 capture coverage to some degree. [As of August 13, coverage is excluded from indicator 4.]
4. It was noted that there are efforts from the president’s initiative discussing how Health Management Information Systems can be used to better monitor PMTCT activities. This effort is still at an early stage. Until the system is further developed, the current indicators and their suggested collection methods will be followed.
5. A number of additional small comments were made including that a paragraph should be included for indicator 2 that states that the proportion of health workers trained in PMTCT care should be judged based on the level of the epidemic in the community and should not necessarily by 100%. Also there were some editorial comments suggested. These were to be provided in hard copy to WHO.
The roles and responsibilities were determined to be as follows:
WHO will finish editing the guide and will make the above mentioned adjustments. It was hoped that in September 2003, this would be completed for publication. This will change of course based on the decision to streamline the different guides.
17 C. Summary of sub-group meeting on Care and Support indicators Submitted by Shanthi Noriega, WHO
The care and support working group acknowledged the importance of the care and support monitoring and evaluation guide. The current push to increase access to care and support for PLWHA makes this guide timely, and there is obvious need to provide national programmes with guidance.
In reviewing the current draft, the working group highlighted the following points: There is a need to reconsider human capacity indicators There is a need to further field-test the indicators. There is a lack of focus on the private sector. More detail is needed in the tables and templates.
Each of these points were addressed in turn.
The current manual contains ten core indicators covering a wide range of care and support needs. However, the MERG working group felt that human capacity indicators were missing and requested indicators related to this be considered. All members agreed that human capacity is an important issue to address, but given the need for further development, they would not be included in this version of the manual. The issue has been turned over to the manual’s drafting group, who will share this point with the larger care and support working group in order to guarantee that this issue is addressed at a later date.
Indicators presented in the guide have been field tested in Africa (Kenya and Ethiopia) and the Dominican Republic. It is acknowledged that further testing is required in different settings, and FHI shared plans to continue field testing indicators in selected Asian countries. The overall experience will feed into the adaptation of indicators and instruments as required.
Editorial issues related to the lack of emphasis on the private sector and additional detail for tables and templates were taken into account. It was clarified that the manual is intended for both public and private national programmes and this will be drawn out in the final draft of the document. The same decision was made regarding the need for more detail in tables and templates.
Overall, the working group felt that the manual represented a good effort in providing national care and support programmes with guidance on monitoring and evaluation. It was agreed that the manual would go to press with minor modifications, but that the larger issues related to additional indicators for human capacity would be acknowledged in this manual and efforts would be made to address this need in the near future.
18 19 ANNEX 2
Seventh Meeting of the UNAIDS Monitoring and Evaluation Reference Group (MERG) – Geneva, Switzerland 28-29 July 2003 WHO, Room D
PROVISIONAL AGENDA
DAY 1 – MONDAY, 28 JULY
8:30 – 9:00 Registration
9:00 – 9:30 Welcome and introduction Paul De Lay Objectives of the Meeting Adoption of the Agenda
9:30 –10:45 Indicator development Chairs: Gabriel Mwaluko/Ties Boerma Young People Orphans (OVC) Care & Support IDU PMTCT
Questions and answers
10:45 – 11:00 UNAIDS and the MERG Kathleen Cravero
11:00 - 11:15 COFFEE / TEA
11:15 – 12:15 Three working groups –one for each of the three available indicator guidelines (Care and Support, Young People, and PMTCT)
12:15 – 13:15 Presentation from each working group followed by plenary discussion
13:15 – 14:15 LUNCH
14:15-17:00 Developments in M&E of HIV/AIDS programs Chairs: Yitades Gebre/Chika Saito
UNGASS country reports: Lessons learnt for Michel Caraël M&E capacity building
Survey on coverage rates for essential services John Novak Preliminary results of the API second round
20 New Challenges in M&E Ties Boerma Presentations followed by plenary discussion
15:30 – 15:45 COFFEE / TEA
DAY 2 – TUESDAY, 29 JULY
09:00 – 12:00 Developments in global M&E initiatives Chair: John Novak
09:00 –9:45 Global HIV/AIDS Monitoring and Evaluation Team (GAMET) Update on GAMET David Wilson Plenary discussion
9:45–10:00 COFFEE / TEA
10:00 – 10:30 Preliminary Update on M&E activities Bernhard Schwartlander in the new WHO
10:30 – 11:15 Update on the Global Fund M&E strategy Brad Herbert
11:15-12:00 Country Response Information System (CRIS) Update on the CRIS Geoff Manthey Plenary discussion
12:00-12:30 Surveillance, Estimates and Projections, latest update Karen Stanecki
12:30 –14:00 LUNCH
14:00 –14:15 UNSSP mid-term evaluation Presentation of the upcoming UNSSP evaluation Reeta Bhatia
14:15 – 15:15 M&E at the Global and Country Levels Scope of Work and Composition of the MERG Paul De Lay Plenary discussion
15:15 –15:30 COFFEE / TEA
15:30 – 16:00 The way forward Paul De Lay Closure and next steps
21 ANNEX 3
MONITORING AND EVALUATION REFERENCE GROUP (MERG)
7th MERG Meeting in Geneva, Switzerland (WHO-Room D) on 28-29 July 2003
LIST OF ATTENDEES
Name Contact details Organization/Country
NATIONAL GOVERNMENTS
1. Yitades GEBRE National HIV/AIDS Prevention and MoH Jamaica Control Program Ministry of Health 2-4 King Street, Kingston, Jamaica Tel: +876 922 2448 Fax: +876 967 1643 E-mail: [email protected]
BILATERAL AGENCIES/NATIONAL GOVERNMENT AGENCIES/ US FUNDED PROJECTS
2. John NOVAK United States Agency for USAID USA International Development 5th Floor RRB 1300 Pennsylvania Avenue N.W. Washington, D.C. 20523-3700, USA Tel: +1 202 712 4814 Fax: +1 202 216 3046 E-mail: [email protected]
3. Deborah RUGG Global AIDS Program CDC USA Centers for Disease Control and Prevention 1600 Clifton Road. Mailstop E41 Atlanta, GA 30333
22 USA Tel: +1 404 498 2796 Fax: +1 404 498 2785 E-mail: [email protected]
4. Erin ECKERT ORC/Macro (Measure Evaluation) ORC/Macro USA 11785 Beltsville Drive, Ste. 300 Calverton Maryland 20703 USA Tel: +1 301 572 0397 Fax: +1 301 572 0999 E-mail: [email protected]
5. Bernard BARRERE Measure Demographic Health Survey Measure USA ORC Macro DHS+ 11785 Beltsville Drive, Calverton ORC Maryland 20705 MACRO USA Tel: +1 301 572 0957 Fax: +1 302 572 0999 E-mail: [email protected]
6. Joshua VOLLE Family Health International FHI USA Evaluation, Surveillance and Research 2101 Wilson Boulevard, Suite 700 Arlington, VA 22201 USA Tel: +1 703 516 9779 Fax: +1 703 516 9781 E-mail: [email protected]
ACADEMIC/RESEARCH INSTITUTES
7. Nicolas MEDA Centre MURAZ Centre Burkina Ministry of Health Biomedical MURAZ Faso Research and Training Institute PO Box 390 Bobo-Dioulasso 01 Burkina Faso Tel: +226 97 26 30 Fax: +226 97 01 77 E-mail: [email protected] [email protected]
8. John CLELAND Centre for Population Studies LSHTM UK London School of Hygiene and Tropical Medicine
23 49-51 Bedford Square London WC1B 3DP Tel: +44 207 299 4621 Fax: +44 207 299 4637 E-mail: [email protected]
COSPONSORS
9. Roeland MONASCH Statistics and Monitoring UNICEF United Nations Children’s Fund R-492 3 United Nations Plaza New York, NY 10017 USA Tel: +1 212 303 7982 Fax: +1 212 824 6490 E-mail: [email protected]
10. Mary MAHY Division of Policy and Planning UNICEF United Nations Children’s Fund H-4A, 3 United Nations Plaza New York, NY 10017 USA Tel: +1 212 327 7247 Fax: +1 212 824 6490 E-mail: [email protected]
11. Joseph ANNAN HIV/AIDS Group UNDP Bureau for Development Policy United Nations Development Programme 1 United Nations Plaza DC1-462 New York, NY 10017 USA Tel: +1 212 906 5074 Fax: +1 212 906 5023 E-mail: [email protected]
12. Chika SAITO HIV/AIDS Group UNDP Bureau for Development Policy United Nations Development Programme 1 United Nations Plaza DC1-462 New York, NY 10017 USA Tel: + 1 212 906 5014 Fax: +1 212 906 5023 E-mail: [email protected]
13. Bongs LAINJO Office of Oversight and Evaluation UNFPA United Nations Population Fund 220 East 42nd Street
24 New York, NY 10017 USA Tel: +1 212 297 5229 Fax: +1 212 297 4938 E-mail : [email protected]
14. Pallavi RAI Technical Cooperation ILO International Labour Office 4, route des Morillons CH-1211 Geneva 22 Tel: +4122 799 6438 Fax: +4122 799 6668 Email: [email protected]
15. Geoffrey GEURTS Internal Oversight Service UNESCO United Nations Educational, Scientific and Cultural Organization 7 place de Fontenoy 75352 Paris France Tel: +33 1 45 68 1236 Fax: +33 1 45 68 5571 E-mail: [email protected]
16. Ties BOERMA Surveillance, Monitoring & Research WHO Evaluation Team Department of HIV/AIDS World Health Organisation 20 Avenue Appia CH-1211 Geneva 27, Switzerland Tel: +41 22 791 1481 Fax: +41 22 791 4834 E-mail: boermat @who.int
17. J.M Garcia CALLEJA FCH/HIV/SMR WHO Surveillance, Monitoring and Research Evaluation Team World Health Organisation 20 Avenue Appia CH-1211 Geneva 27, Switzerland Tel: +41 22 791 4252 Fax: +41 22 791 4834 E-mail: [email protected]
18. Cyril PERVILHAC Surveillance, Research, Monitoring & WHO Evaluation Team Department of HIV/AIDS World Health Organisation 20 Avenue Appia
25 CH-1211 Geneva 27, Switzerland Tel: +41 22 791 1323 Fax: +41 22 791 4834 E-mail: pervilhacc @who.int
19. Kevin O'REILLY Surveillance, Research, Monitoring & WHO Evaluation Team Department of HIV/AIDS World Health Organisation 20 Avenue Appia CH-1211 Geneva 27, Switzerland Tel: +41 22 791 4507 Fax: +41 22 791 4834 E-mail: oreillyk @who.int
20. Bernhard Family and Community Health WHO SCHWARTLANDER Department of HIV/AIDS World Health Organisation 20 Avenue Appia CH-1211 Geneva 27, Switzerland Tel: +41 22 791 4705 Fax: +41 22 791 4834 E-mail: schwartlanderb @who.int
21. David WILSON Monitoring and Evaluation World Bank Support Team Global HIV/AIDS Office The World Bank 1818 H. Street, N.W. Washington D.C. 20433 USA Tel: +1 202 458 2537 Fax: +1 202 522 7396 E-mail: [email protected] [email protected]
NON GOVERNMENTAL ORGANIZATIONS
22. Gabriel MWALUKO Tanzania-Netherlands project to TANESA Tanzania support AIDS control in Mwanza Region P O Box 434 MWANZA, Tanzania Tel: +255 282 500236 Fax : +255 282 502458 Mobile: +255 (0) 744 274545 E-mail : [email protected]
26 GLOBAL FUND SECRETARIAT
23. Brad HERBERT Global Fund to Fight AIDS, GFATM Switzerland Tuberculosis and Malaria 53, Avenue Louis-Casaï 1216 Geneva-Cointrin, Switzerland Tel: +41 22 791 17 12 Fax: +41 22 791 17 01 E-mail: [email protected]
UNAIDS SECRETARIAT
24. Kathleen CRAVERO Executive Office UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 4716 Fax: +41 22 791 4187 E-mail: [email protected]
25. Paul DE LAY Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 4534 Fax: +41 22 791 4768 E-mail: [email protected]
26. Michel CARAEL Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 4651 Fax: +41 22 791 4768 E-mail: [email protected]
27 27. Nicole MASSOUD Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 4694 Fax: +4122 791 4768 E-mail: [email protected]
28. Soichi KOIKE Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1502 Fax: +4122 791 4768 E-mail: [email protected]
29. Zero AKYOL Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 2522 Fax: +4122 791 4768 E-mail: [email protected] 30. Louise BERRY Monitoring & Evaluation Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 4915 Fax: +4122 791 4768 E-mail: [email protected] 31. Geoff MANTHEY Monitoring & Evaluation Team UNAIDS (CRIS) UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1373 Fax: +4122 791 4188 E-mail: [email protected]
32. Patrick WHITAKER Monitoring & Evaluation Team UNAIDS (CRIS) UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1372 Fax: +4122 791 4188 E-mail: whitakerp @unaids.org
33. Karianne BYE Monitoring & Evaluation Team UNAIDS (CRIS) UNAIDS
28 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1359 Fax: +4122 791 4188 E-mail: byek @unaids.org
34. Catherine HANKINS Strategic Information UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 3865 Fax: +4122 791 4898 E-mail: hankinsc @unaids.org
35. Karen STANECKI Epidemic & Impact Monitoring Team UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1662 Fax: +4122 791 4898 E-mail: staneckik @unaids.org
36. Reeta BHATIA UN System Programme Review UNAIDS UNAIDS 20 avenue Appia CH – 1211 Geneva 27 Tel: +41 22 791 1371 Fax: +4122 791 4768 E-mail: bhatiar @unaids.org
37. Karl-Lorenz Dehne Dr Karl-Lorenz Dehne UNAIDS UNAIDS Vienna International Center, Room D1470 Wagramer Strasse 5, A-1400 Vienna, Austria Tel: +43 1 26060 4662 Fax: +43 1 26060 7549 E-mail: [email protected]
29 ANNEX 4
MONITORING AND EVALUATION REFERENCE GROUP (MERG)
7th MERG Meeting in Geneva, Switzerland (WHO-Room D) on 28-29 July 2003
UNABLE TO ATTEND
Name Contact details Organization/Country
NATIONAL GOVERNMENTS
1. Sylvia ANIE Ghana AIDS Commission GAC Ghana P.O. Box CT 5169 Cantonments Accra Ghana Tel: +233 21 782 262 /263 Fax: +233 21 782 264 E-mail: [email protected]
30 BILATERAL AGENCIES/NATIONAL GOVERNMENT AGENCIES/ US FUNDED PROJECTS
2. Phil COMPERNOLLE Health and HIV DFID UK Evaluation – HIV/AIDS Department for International Development London UK Tel: +44 1355 843640 Fax: E-mail: [email protected]
3. Valerie YOUNG Performance Review Branch CIDA Canada Canadian International Development Agency 200 Promenade du Portage Hull, Quebec K1A 0G4, Canada Tel : +819 994 6137 Fax : +819 953 9130 E-mail : [email protected]
4. George BICEGO Global AIDS Program CDC USA Centers for Disease Control and Prevention 1600 Clifton Road. NE Atlanta, GA 30333 USA Tel: +1 404 639-3534 Fax: +1 404 639 4268 E-mail : [email protected]
5. John STOVER The Futures Group International Futures USA 80 Glastonbury Blvd. Group Glastonbury, Connecticut 06033 USA Tel: +1 860 633 3501 Fax: +1 860 657 3918 E-mail: [email protected]
ACADEMIC/RESEARCH INSTITUTES
6. Eiliana MONTERO-ROJAS Escuela de Estadística University of Costa Rica Universidad de Costa Rica Costa Rica San José, Costa Rica Central America Tel: +506 280-5194 Fax: +506 207 4809 E-mail: [email protected]
31 7. Françoise DUBOIS-ARBER University Institute of Social and IUMSP Switzerland Preventive Medicine, University of Lausanne 17 rue du Bugnon, CH-1005 Lausanne Switzerland Tel: +41 21 314 7292/90 Fax: +41 21 314 7244 E-mail: [email protected] 8. Kong-lai ZHANG Department of Epidemiology PUMC China Peking Union Medical College 5 Dong Dan San Tiao Beijing China 100005 Tel: +86 10 652 96973 Fax: +86 10 652 88170 E-mail: [email protected] 9. Napaporn HAVANON Department of Graduate School Thailand Sri Nakharinwirot University Sukhumvit Soi 23 Bangkok Tel/Fax: 662 258 4119, 260 0133 E-mail: [email protected] E-mail : [email protected]
COSPONSORS 10. To be identified Division for Operations and Analysis UNDCP United Nations International Drug Control Program P.O. Box 500 Vienna A1400 Austria Tel: +43 1 26060 5450 Fax: +43 1 26060 5896 E-mail: 11. Benjamin ALLI Technical Cooperation ILO International Labour Office 4, route des Morillons CH-1211 Geneva 22 Tel: +4122 799 6438 Fax: +4122 799 6668 Email: [email protected] 12. Susan STOUT Monitoring and Evaluation World Bank Support Team Global HIV/AIDS Office The World Bank 1818 H. Street, N.W. Washington D.C. 20433 USA Tel: +1 202 458 2537 Fax: +1 202 522 7396 E-mail: [email protected]
32 NON GOVERNMENTAL ORGANIZATIONS 13. Jacqueline ActionAid Africa ActionAid Zimbabwe BATARINGAYA Regional Office International 16 York Avenue Newlands Harare Zimbabwe Tel: +263 4 788122/3 Fax: +263 4 788 124 E-mail: [email protected]
EUROPEAN UNION 14. Charles TODD Human and Social Development EU Belgium Unit (B/3) DG Development European Commission B-1049 Bruxelles Belgium Tel: +32-2-299-0289 Fax: +32-2-296-3697 E-mail: [email protected]
33